07:25 AM EDT, 06/13/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Friday that Colombia's National Institute of Drug and Food Surveillance has approved Orladeyo to prevent hereditary angioedema attacks in patients at least 12 years old.

The company said it has an exclusive collaboration with Pint Pharma for Orladeyo in the pan-Latin America region, with Pint in charge of all marketing authorizations and commercialization in the region.

Orladeyo has also been approved in Chile, Argentina, Brazil, Mexico and Peru, the company said.